FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589947642> ?p ?o ?g. }

• W2589947642 endingPage "e478" @default.
• W2589947642 startingPage "e470" @default.
• W2589947642 abstract "Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese critically ill patients. We aimed to compare pharmacokinetics of piperacillin in severely obese and nonobese patients with severe sepsis or septic shock. We hypothesized that plasma concentration variability would expose the critically ill to both piperacillin under and overdosing. Methods: Prospective comparative study. Consecutive critically ill severely obese (body mass index, > 35 kg/m 2 ) and nonobese patients (body mass index, < 30 kg/m 2 ) were treated with 16 g/2 g/24 hr continuous piperacillin-tazobactam infusion. Piperacillin plasma concentration was measured every 12 hours over a 7-day period by high-pressure liquid chromatography. Unbound piperacillin plasma concentration and fractional time of plasma concentration spent over 64 mg/L (4-fold the minimal inhibitory concentration for Pseudomonas aeruginosa ) were compared between the two groups. We performed 5,000 Monte Carlo simulations for various dosing regimens and minimal inhibitory concentration and calculated the probability to spend 100% of the time over 64 mg/L. Results: We enrolled 11 severely obese and 12 nonobese patients and obtained 294 blood samples. We did not observe a statistically significant difference in piperacillin plasma concentrations over time between groups. The fractional time over 64 mg/L was 64% (43–82%) and 93% (85–100%) in obese and nonobese patients, respectively, p = 0.027 with intra- and intergroup variability. Five nonobese and two obese patients experienced potentially toxic piperacillin plasma concentrations. When 64 mg/L was targeted, Monte Carlo simulations showed that 12 g/1.5 g/24 hr was inadequate in both groups and 16 g/2 g/24 hr was adequate only in nonobese patients. Conclusion: Using a conventional dosing of 16 g/2 g/24 hr continuous infusion, obese patients were more likely than nonobese patients to experience piperacillin underdosing when facing high minimal inhibitory concentration pathogens. The present study suggests that piperacillin drug monitoring might be necessary in the sickest patients who are at the highest risk of unpredictable plasma concentration exposing them to overdose, toxicity, underdosing, and treatment failure." @default.
• W2589947642 created "2017-03-03" @default.
• W2589947642 creator A5006721778 @default.
• W2589947642 creator A5011839161 @default.
• W2589947642 creator A5012034145 @default.
• W2589947642 creator A5016058204 @default.
• W2589947642 creator A5027282400 @default.
• W2589947642 creator A5052475656 @default.
• W2589947642 creator A5064508525 @default.
• W2589947642 creator A5091142950 @default.
• W2589947642 creator A5091489538 @default.
• W2589947642 date "2017-05-01" @default.
• W2589947642 modified "2023-10-14" @default.
• W2589947642 title "Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under– and Overdosing*" @default.
• W2589947642 cites W1558882059 @default.
• W2589947642 cites W1580056596 @default.
• W2589947642 cites W1967088772 @default.
• W2589947642 cites W1971624521 @default.
• W2589947642 cites W1972649334 @default.
• W2589947642 cites W1975564692 @default.
• W2589947642 cites W1983798132 @default.
• W2589947642 cites W1989723632 @default.
• W2589947642 cites W1993397663 @default.
• W2589947642 cites W1999632608 @default.
• W2589947642 cites W2007821053 @default.
• W2589947642 cites W2013388908 @default.
• W2589947642 cites W2023521548 @default.
• W2589947642 cites W2026332974 @default.
• W2589947642 cites W2043670977 @default.
• W2589947642 cites W2047635738 @default.
• W2589947642 cites W2050496243 @default.
• W2589947642 cites W2059267457 @default.
• W2589947642 cites W2076374902 @default.
• W2589947642 cites W2079691262 @default.
• W2589947642 cites W2093814712 @default.
• W2589947642 cites W2099916537 @default.
• W2589947642 cites W2102663241 @default.
• W2589947642 cites W2105898693 @default.
• W2589947642 cites W2114671887 @default.
• W2589947642 cites W2117673632 @default.
• W2589947642 cites W2123184270 @default.
• W2589947642 cites W2128032969 @default.
• W2589947642 cites W2143024482 @default.
• W2589947642 cites W2149974939 @default.
• W2589947642 cites W2150758178 @default.
• W2589947642 cites W2153641174 @default.
• W2589947642 cites W2153997139 @default.
• W2589947642 cites W2271687636 @default.
• W2589947642 cites W2442246762 @default.
• W2589947642 cites W2798604223 @default.
• W2589947642 doi "https://doi.org/10.1097/ccm.0000000000002287" @default.
• W2589947642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28240688" @default.
• W2589947642 hasPublicationYear "2017" @default.
• W2589947642 type Work @default.
• W2589947642 sameAs 2589947642 @default.
• W2589947642 citedByCount "22" @default.
• W2589947642 countsByYear W25899476422017 @default.
• W2589947642 countsByYear W25899476422018 @default.
• W2589947642 countsByYear W25899476422019 @default.
• W2589947642 countsByYear W25899476422020 @default.
• W2589947642 countsByYear W25899476422021 @default.
• W2589947642 countsByYear W25899476422023 @default.
• W2589947642 crossrefType "journal-article" @default.
• W2589947642 hasAuthorship W2589947642A5006721778 @default.
• W2589947642 hasAuthorship W2589947642A5011839161 @default.
• W2589947642 hasAuthorship W2589947642A5012034145 @default.
• W2589947642 hasAuthorship W2589947642A5016058204 @default.
• W2589947642 hasAuthorship W2589947642A5027282400 @default.
• W2589947642 hasAuthorship W2589947642A5052475656 @default.
• W2589947642 hasAuthorship W2589947642A5064508525 @default.
• W2589947642 hasAuthorship W2589947642A5091142950 @default.
• W2589947642 hasAuthorship W2589947642A5091489538 @default.
• W2589947642 hasBestOaLocation W25899476422 @default.
• W2589947642 hasConcept C111113717 @default.
• W2589947642 hasConcept C112705442 @default.
• W2589947642 hasConcept C126322002 @default.
• W2589947642 hasConcept C176947019 @default.
• W2589947642 hasConcept C2777628635 @default.
• W2589947642 hasConcept C2777637488 @default.
• W2589947642 hasConcept C2777858937 @default.
• W2589947642 hasConcept C2778193466 @default.
• W2589947642 hasConcept C2778266534 @default.
• W2589947642 hasConcept C2778384902 @default.
• W2589947642 hasConcept C2780221984 @default.
• W2589947642 hasConcept C42219234 @default.
• W2589947642 hasConcept C501593827 @default.
• W2589947642 hasConcept C523546767 @default.
• W2589947642 hasConcept C54355233 @default.
• W2589947642 hasConcept C71924100 @default.
• W2589947642 hasConcept C86803240 @default.
• W2589947642 hasConcept C89423630 @default.
• W2589947642 hasConcept C90924648 @default.
• W2589947642 hasConcept C98274493 @default.
• W2589947642 hasConceptScore W2589947642C111113717 @default.
• W2589947642 hasConceptScore W2589947642C112705442 @default.
• W2589947642 hasConceptScore W2589947642C126322002 @default.
• W2589947642 hasConceptScore W2589947642C176947019 @default.
• W2589947642 hasConceptScore W2589947642C2777628635 @default.

• next